Q2 2023 EPS Estimates for GT Biopharma, Inc. (NASDAQ:GTBP) Lifted by Analyst

Posted by on May 20th, 2023

GT Biopharma, Inc. (NASDAQ:GTBP – Get Rating) – Research analysts at HC Wainwright upped their Q2 2023 EPS estimates for shares of GT Biopharma in a report released on Wednesday, May 17th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($0.10) for the quarter, up from their previous estimate of ($0.15). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for GT Biopharma’s current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for GT Biopharma’s Q3 2023 earnings at ($0.11) EPS, Q4 2023 earnings at ($0.12) EPS and FY2023 earnings at ($0.35) EPS.

Separately, EF Hutton Acquisition Co. I reaffirmed a “hold” rating and set a $2.00 target price on shares of GT Biopharma in a report on Friday, March 31st.

GT Biopharma Trading Down 6.4 %

GTBP opened at $0.27 on Friday. GT Biopharma has a 12 month low of $0.26 and a 12 month high of $3.29. The firm’s fifty day simple moving average is $0.43 and its 200 day simple moving average is $0.93. The stock has a market capitalization of $10.14 million, a P/E ratio of -0.53 and a beta of 0.84.

Institutional Investors Weigh In On GT Biopharma

Several large investors have recently modified their holdings of GTBP. Armistice Capital LLC bought a new position in shares of GT Biopharma in the fourth quarter valued at $3,003,000. Millennium Management LLC purchased a new stake in GT Biopharma during the second quarter worth about $730,000. Baskin Financial Services Inc. purchased a new position in shares of GT Biopharma in the fourth quarter worth about $134,000. Wells Fargo & Company MN increased its stake in shares of GT Biopharma by 18,317.6% in the fourth quarter. Wells Fargo & Company MN now owns 100,560 shares of the company’s stock worth $89,000 after purchasing an additional 100,014 shares in the last quarter. Finally, Atria Wealth Solutions Inc. increased its stake in shares of GT Biopharma by 587.2% in the second quarter. Atria Wealth Solutions Inc. now owns 68,720 shares of the company’s stock worth $205,000 after purchasing an additional 58,720 shares in the last quarter. 7.62% of the stock is currently owned by institutional investors and hedge funds.

About GT Biopharma

(Get Rating)

GT Biopharma, Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system natural killer cells (NK cells).

Recommended Stories

Receive News & Ratings for GT Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GT Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.